RTP Mobile Logo
Gastrointestinal Cancer Tumor Panel: Clinical Investigators Provide Their Perspectives on Current Cases and Clinical Issues in the Management of Colorectal, Gastric and Pancreatic Cancer
Released October 2015

Featuring interviews with Drs Axel Grothey, MD and Eileen M O’Reilly. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in these subcategories surpass those attributed to CRC. Recently published randomized, controlled studies have led to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. A number of pivotal data sets illustrating the benefits of several novel agents indicate that additional therapeutic options may soon be available that will warrant consideration. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. This CME program uses one-on-one interviews with 2 leading GI clinical investigators who served as faculty at a recent satellite symposium to discuss cases and questions submitted by attendees. This program will assist practicing clinicians in formulating up-to-date and appropriate clinical management strategies.

    LEARNING OBJECTIVES

    • Communicate the benefits and risks of approved anti-VEGF and other targeted biologic therapies to patients with metastatic CRC, and develop an evidence-based algorithm to sequence these available options based on disease- and patient-specific characteristics.
    • Individualize local and systemic treatment for patients with metastatic CRC that is isolated to the liver.
    • Implement a clinical plan for the management of advanced HER2-positive gastric cancer, incorporating existing and emerging targeted treatments.
    • Appreciate available clinical research data documenting the efficacy of ramucirumab in advanced gastric or gastroesophageal junction cancer, and discern how this agent can be optimally integrated into clinical practice for patients with HER2-negative and HER2-positive disease.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in patients with gastric cancer.
    • Consider age, performance status and other clinical factors in the selection of systemic therapy for patients with metastatic pancreatic adenocarcinoma.
    • Describe the proposed mechanism of action and available research data with ruxolitinib in pancreatic cancer, and use this information to counsel appropriate patients regarding ongoing trials evaluating this novel approach.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr GrotheyContracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly, Pfizer Inc, Sanofi. Dr O’ReillyConsulting Agreements: Abbott Laboratories, Aduro Biotech, Amgen Inc, Astellas Scientific and Medical Affairs Inc, Celgene Corporation, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Cipla Ltd, EntreMed Inc, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, IntegraGen, Jennerex Inc, Lilly, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi, Silenseed Ltd, Vicus Therapeutics; Contracted Research: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Momenta Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Polaris Group, Roche Laboratories Inc, Vicus Therapeutics.


    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Incyte Corporation, Lilly and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2015
    Expiration date: October 2016


    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Gastrointestinal Cancer Tumor Panel: Clinical Investigators Provide Their Perspectives on Current Cases and Clinical Issues in the Management of Colorectal, Gastric and Pancreatic Cancer
Released October 2015

Featuring interviews with Drs Axel Grothey, MD and Eileen M O’Reilly. (Audio Content)

Read print: